[Other] Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Shriyam Post time The day before yesterday 11:11 | Show all posts |Read mode
Reward20points

Authors:Diwakar Davar; Robert  M. Morrison; Amiran  K. Dzutsev; Arivarasan Karunamurthy; Joe-Marc Chauvin; Florent Amatore; Julie  S. Deutsch; Rodrigo  X. Das Neves; Richard  R. Rodrigues; John  A. McCulloch; Hong Wang; Douglas  J. Hartman; Jonathan  H. Badger; Miriam  R. Fernandes; Yulong Bai; Jie Sun; Alicia  M. Cole; Poonam Aggarwal; Jennifer  R. Fang; Christopher Deitrick; Riyue Bao; Umamaheswar Duvvuri; Shaum  S. Sridharan; Seungwon  W. Kim; M.  Haroon Asif Choudry; Matthew  P. Holtzman; James  F. Pingpank; James  Patrick O'Toole; Richelle DeBlasio; Yang Jin; Quanquan Ding; Wentao Gao; Christopher Groetsch; Ornella Pagliano; Amy Rose; Corey Urban; Jagjit Singh; Prajan Divarkar; David Mauro; Dmitri Bobilev; James Wooldridge; Art Krieg; Matthew  G. Fury; Jeffrey  R. Whiteaker; Lei Zhao; Amanda  G. Paulovich; Yana  G. Najjar; Jason  J. Luke; John  M. Kirkwood; Janis  M. Taube; Hyun  Jung Park; Giorgio Trinchieri; Hassane  M. Zarour

DOI:10.2139/ssrn.4870953

Article link:http://dx.doi.org/10.2139/ssrn.4870953

Article Source:Elsevier BV

Best Answer

Please adopt

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
ntasnim687 Post time The day before yesterday 11:11 | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Senior Member
  • post

  • reply

  • points

    730

Latest Reply

Return to the list